Incyte
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.
Phase 2
Completed
- Conditions
- Philadelphia PositiveAcute Lymphoblastic LeukemiaBCR-ABL Positive
- Interventions
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 44
- Registration Number
- NCT01641107
- Locations
- 🇮🇹
Dipartimento Area Medica - Presidio Ospedaliero "C. e G.Mazzoni", Ascoli, Italy
🇮🇹Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI, Ancona, Italy
🇮🇹Azienda Ospedaliera - Papa Giovanni XXIII, Bergamo, Italy
A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 50
- Registration Number
- NCT01634087
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
- First Posted Date
- 2012-07-04
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 87
- Registration Number
- NCT01633372
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇨🇦St. Paul's Hospital, Vancouver, British Columbia, Canada
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Phase 3
Completed
- Conditions
- Polycythemia Vera
- Interventions
- First Posted Date
- 2012-07-03
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 110
- Registration Number
- NCT01632904
A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis
- First Posted Date
- 2012-06-22
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 106
- Registration Number
- NCT01626573
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 136
- Registration Number
- NCT01604889
Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
Phase 2
Completed
- Conditions
- Primary MyelofibrosisPost-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera Myelofibrosis
- Interventions
- First Posted Date
- 2011-10-04
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 45
- Registration Number
- NCT01445769
Study of Ruxolitinib in Pancreatic Cancer Patients
Phase 2
Completed
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2018-02-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 136
- Registration Number
- NCT01423604
Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
- First Posted Date
- 2011-05-05
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 66
- Registration Number
- NCT01348490
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
- First Posted Date
- 2011-04-22
- Last Posted Date
- 2014-03-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 41
- Registration Number
- NCT01340651
© Copyright 2025. All Rights Reserved by MedPath